Previous 10 | Next 10 |
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“ HUTCHMED ”) today announced that Takeda ( TSE:4502/NYSE:TAK ) has submitted a New Drug Application (“...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epitheli...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in China. The br...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administratio...
2023-08-21 11:31:53 ET More on Hutchison China MediTech Hutchmed: Attractive Chinese R&D Giant HUTCHMED (China) Limited ( HCM ) Q2 2023 Earnings Call Transcript Hutchmed starts registration phase for cancer trials after talks with Chinese regulator Hu...
— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China,...
2023-08-11 17:59:00 ET Summary Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems of China and the U.S., working to get its products ...
2023-08-07 13:28:03 ET Gainers: Nektar Therapeutics ( NKTR ) +87% . Enveric Biosciences ( ENVB ) +47% . Sequans Communications S.A. ( SQNS ) +31% . Tabula Rasa HealthCare ( TRHC ) +31% . Missfresh Limited ( MF ) +29% . Sovos ...
2023-08-07 10:15:28 ET Gainers: Poseida Therapeutics ( PSTX ) +33% . Tabula Rasa HealthCare ( TRHC ) +32% . Mallinckrodt plc ( MNK ) +17% . Assertio Holdings ( ASRT ) +18% . Palatin Technologies ( PTN ) +16% . Losers: Sag...
2023-08-02 17:57:42 ET TriNet Group Inc ( NYSE: TNET ) on Wednesday announced it has priced $400M in aggregate principal amount of its 7.125% senior notes due 2031 in a private offering. TriNet also expects to enter into an amendment to its revolving credit facility that would...
News, Short Squeeze, Breakout and More Instantly...
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA 1 ...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignan...